| |
|
|
|
Xtalks, Online
2024-10-29
After bringing groundbreaking treatment advancements to oncology, CAR T therapies are beginning to show promise in additional therapeutic areas. As these advanced therapies enter clinical trials in new patient communities, successful programs rely on understanding which elements of the oncology construct can be seamlessly applied in the new paradigm.
In this webinar, panelists will discuss how the collaboration between therapeutically aligned teams impacts study delivery for CAR T in autoimmune disease and neurology clinics. Discussions will include considerations for sponsor, site, and patient stakeholders. Don’t miss this chance to learn from the successful implementation of CAR T trials and to ask the panelists your own questions.
Keywords: Drug Development, Oncology, CAR-T, CAR-T Immunotherapy, Therapeutic Areas, CAR T Cells, T Cells, CAR T-Cell Therapy, Cell and Gene Therapy, Cell & Gene Therapies, CGT
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Simran Padam, MD, Medical Director, Medical Affairs, Hematology, Oncology, & Rare Disease, Worldwide Clinical Trials
Dr. Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease & Cellular and Genetic Medicines, Worldwide Clinical Trials
Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
Chris Jenkins, Founder, CEO, Sabai
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-29
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|